BRIEF-Sandoz Group Signs Global Collaboration Agreement With Henlius

Reuters

04-29

BRIEF-Sandoz Group Signs Global Collaboration Agreement With Henlius

April 29 (Reuters) - SANDOZ GROUP AG SDZ.S:

SANDOZ ENTERS GLOBAL COLLABORATION LICENSE AGREEMENT WITH HENLIUS TO COMMERCIALIZE LEADING ONCOLOGY THERAPY, IPILIMUMAB, IN MULTIPLE INDICATIONS
SIGNS GLOBAL COLLABORATION AGREEMENT WITH HENLIUS
AGREEMENT VALUED AT UP TO USD 301 MILLION
CORE SEQUENCE PATENT FOR IPILIMUMAB EXPIRED IN MARCH 2025 IN US AND WILL EXPIRE NO LATER THAN FEBRUARY 2026 IN EU
TO COMMERCIALIZE A BIOSIMILAR OF LEADING ONCOLOGY THERAPY, IPILIMUMAB
AGREEMENT IS MILESTONE-BASED FOR A TOTAL CONSIDERATION OF UP TO USD 301 MILLION, INCLUDING AN UPFRONT PAYMENT OF USD 31 MILLION, AND WILL TARGET NET REFERENCE-MEDICINE SALES OF USD 2.5 BILLION

Source text: ID:nGNE8k7F37

Further company coverage: SDZ.S

(Gdansk Newsroom)

((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2531754916"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2531754916\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2531754916?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-29 23:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2531754916","market":"nz","top_or_hot":-1,"title":"BRIEF-Sandoz Group Signs Global Collaboration Agreement With Henlius","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Sandoz Group Signs Global Collaboration Agreement With Henlius</title></head><body><p><span>April 29 (Reuters)</span><span> - </span>SANDOZ GROUP AG <span>SDZ.S</span>:</p><ul><li><p>SANDOZ ENTERS GLOBAL COLLABORATION LICENSE AGREEMENT WITH HENLIUS TO COMMERCIALIZE LEADING ONCOLOGY THERAPY, IPILIMUMAB, IN MULTIPLE INDICATIONS</p></li><li><p>SIGNS GLOBAL COLLABORATION AGREEMENT WITH HENLIUS</p></li><li><p>AGREEMENT VALUED AT UP TO USD 301 MILLION</p></li><li><p>CORE SEQUENCE PATENT FOR IPILIMUMAB EXPIRED IN MARCH 2025 IN US AND WILL EXPIRE NO LATER THAN FEBRUARY 2026 IN EU</p></li><li><p>TO COMMERCIALIZE A BIOSIMILAR OF LEADING ONCOLOGY THERAPY, IPILIMUMAB</p></li><li><p>AGREEMENT IS MILESTONE-BASED FOR A TOTAL CONSIDERATION OF UP TO USD 301 MILLION, INCLUDING AN UPFRONT PAYMENT OF USD 31 MILLION, AND WILL TARGET NET REFERENCE-MEDICINE SALES OF USD 2.5 BILLION</p></li></ul><p>Source text: <span>ID:nGNE8k7F37</span></p><p>Further company coverage: <span>SDZ.S</span></p><p> (Gdansk Newsroom)</p><p> ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Sandoz Group Signs Global Collaboration Agreement With Henlius</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Sandoz Group Signs Global Collaboration Agreement With Henlius\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-04-29 23:02</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Sandoz Group Signs Global Collaboration Agreement With Henlius</title></head><body><p><span>April 29 (Reuters)</span><span> - </span>SANDOZ GROUP AG <span>SDZ.S</span>:</p><ul><li><p>SANDOZ ENTERS GLOBAL COLLABORATION LICENSE AGREEMENT WITH HENLIUS TO COMMERCIALIZE LEADING ONCOLOGY THERAPY, IPILIMUMAB, IN MULTIPLE INDICATIONS</p></li><li><p>SIGNS GLOBAL COLLABORATION AGREEMENT WITH HENLIUS</p></li><li><p>AGREEMENT VALUED AT UP TO USD 301 MILLION</p></li><li><p>CORE SEQUENCE PATENT FOR IPILIMUMAB EXPIRED IN MARCH 2025 IN US AND WILL EXPIRE NO LATER THAN FEBRUARY 2026 IN EU</p></li><li><p>TO COMMERCIALIZE A BIOSIMILAR OF LEADING ONCOLOGY THERAPY, IPILIMUMAB</p></li><li><p>AGREEMENT IS MILESTONE-BASED FOR A TOTAL CONSIDERATION OF UP TO USD 301 MILLION, INCLUDING AN UPFRONT PAYMENT OF USD 31 MILLION, AND WILL TARGET NET REFERENCE-MEDICINE SALES OF USD 2.5 BILLION</p></li></ul><p>Source text: <span>ID:nGNE8k7F37</span></p><p>Further company coverage: <span>SDZ.S</span></p><p> (Gdansk Newsroom)</p><p> ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nTUA3DHRXJ:1","article_id":"2531754916","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2531754916","pubTimestamp":1745938928,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Sandoz Group Signs Global Collaboration Agreement With HenliusApril 29 (Reuters) - SANDOZ GROUP AG SDZ.S:SANDOZ ENTERS GLOBAL COLLABORATION LICENSE AGREEMENT WITH HENLIUS TO COMMERCIALIZE LEADIN","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"简介-山德士集团与复宏汉霖签署全球合作协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":0.9},"content_text":"BRIEF-Sandoz Group Signs Global Collaboration Agreement With HenliusApril 29 (Reuters) - SANDOZ GROUP AG SDZ.S:SANDOZ ENTERS GLOBAL COLLABORATION LICENSE AGREEMENT WITH HENLIUS TO COMMERCIALIZE LEADING ONCOLOGY THERAPY, IPILIMUMAB, IN MULTIPLE INDICATIONSSIGNS GLOBAL COLLABORATION AGREEMENT WITH HENLIUSAGREEMENT VALUED AT UP TO USD 301 MILLIONCORE SEQUENCE PATENT FOR IPILIMUMAB EXPIRED IN MARCH 2025 IN US AND WILL EXPIRE NO LATER THAN FEBRUARY 2026 IN EUTO COMMERCIALIZE A BIOSIMILAR OF LEADING ONCOLOGY THERAPY, IPILIMUMABAGREEMENT IS MILESTONE-BASED FOR A TOTAL CONSIDERATION OF UP TO USD 301 MILLION, INCLUDING AN UPFRONT PAYMENT OF USD 31 MILLION, AND WILL TARGET NET REFERENCE-MEDICINE SALES OF USD 2.5 BILLIONSource text: ID:nGNE8k7F37Further company coverage: SDZ.S (Gdansk Newsroom) ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}